Biopharmaceutical company Humanigen, Inc. (HGEN) announced Monday that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase 3 study of lenzilumab in patients with COVID-19 in Brazil.
from RTT - Biotech https://ift.tt/31wJMEo
via IFTTT
No comments:
Post a Comment